Latest News - Clinical Trials

Friday, April 21, 2017 | Clinical Trials

Powered by CIRM Grant, jCyte Launches New Clinical Trial

Cell therapy company jCyte is launching a phase 2b clinical trial to test the safety and efficacy of its developmental retinitis pigmentosa (RP) treatment, jCell. The company is recruiting 70 pa…

Read the full story

Thursday, April 20, 2017 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Announces Completion of Patient Enrollment in Phase 1/2 Clinical Trial of CLS-TA in Diabetic Macular Edema

Clearside Biomedical announced completion of enrollment of an exploratory clinical trial (HULK trial) of CLS-TA for suprachoroidal administration, its proprietary suspension formulation of the cortico…

Read the full story

Thursday, April 20, 2017 | Clinical Trials

Eyevensys Receives Approval from the UK Medicines and Healthcare Products Regulatory Agency to Advance its EyeCET Platform Into Clinical Development

Eyevensys announced it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to advance its technology into clinical development. Eyevensys is developing its pro…

Read the full story

Wednesday, April 12, 2017 | Clinical Trials, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Positive 6-Month Topline Safety and Efficacy Results for Rhopressa 0.02%

Aerie Pharmaceuticals reported the successful 6-month topline safety and efficacy results of its Rocket 4 phase 3 clinical trial for product candidate Rhopressa, a novel once-daily eye drop being test…

Read the full story

Tuesday, April 11, 2017 | Clinical Trials, Nicox

Nicox Announces PDUFA Date for Allergic Conjunctivitis Drug Candidate Zerviate

Nicox announced that the FDA has set a PDUFA date of September 8, 2017 for its decision on the new drug application (NDA) for Zerviate (cetirizine ophthalmic solution) 0.24%, Nicox's novel, propri…

Read the full story

Tuesday, April 11, 2017 | Clinical Trials

Eyevensys Receives Approval From the French Product Security Regulatory Agency ANSM to Advance its EyeCET Platform Into Clinical Development

Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, announced it has received approval from the French product security regulatory agency 'Agence Nationale de S&…

Read the full story

Tuesday, April 11, 2017 | Clinical Trials, Inotek Pharmaceuticals

Inotek Completes Patient Recruitment in Phase 2 Trial of a Fixed-Dose Combination of Trabodenoson and Latanoprost

Inotek Pharmaceuticals announced the completion of the active recruitment phase of the phase 2 dose-ranging trial of a fixed-dose combination (FDC) of trabodenoson and latanoprost for the treatment of…

Read the full story

Monday, April 10, 2017 | Clinical Trials, Ohr Pharmaceutical

Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet AMD

Ohr Pharmaceutical announced that it plans to amend the ongoing clinical trial investigating Squalamine in wet age-related macular degeneration (MAKO Study) to enable efficacy analyses by the end of c…

Read the full story

Tuesday, April 04, 2017 | Clinical Trials, Genentech

Genentech Presents Positive Phase 3 Results for Giant Cell Arteritis

Genentech presented for the first time its results from GiACTA, a phase 3 study which evaluated Actemra (tocilizumab) in people with giant cell arteritis (GCA), to an ophthalmology audience. The abstr…

Read the full story

Monday, April 03, 2017 | Clinical Trials

New Clinical Trial for Early-Stage Eye Melanoma Offers Study of Targeted Therapy

A first-of-its-kind, potentially groundbreaking new option for treating a form of eye cancer is now in its first phase 1 clinical research trial at Wills Eye Hospital in Philadelphia. The treatment, c…

Read the full story

Friday, March 31, 2017 | Clinical Trials

Opthea to Provide Update on OPT-302 Phase 1/2A Wet AMD Clinical Trial

Opthea will host a conference call and webcast at 10:30 am Australian Eastern Standard Time on Monday 3 April (8:30 pm US EST on Sunday, April 2). The company will discuss results from its phase 1/2A …

Read the full story

Thursday, March 30, 2017 | Clinical Trials

Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment of Primary Ocular Melanoma

Aura Biosciences announced that it has enrolled and dosed the first patient in its phase 1b clinical trial of light-activated AU-011, an investigational, first-in-class targeted therapy in development…

Read the full story

Wednesday, March 22, 2017 | Clinical Trials, Management/Leadership

ClarVista Medical Completes Milestone to Advance Novel Modular Intraocular Lens for Cataract Lens Replacement

ClarVista Medical, a privately-held ophthalmic device company developing the Harmoni Modular IOL System, a novel IOL used to restore vision after cataract surgery, announced that several feasibility t…

Read the full story

Tuesday, March 21, 2017 | Clinical Trials, Partnerships

Nemus Bioscience Signs Agreement with Nanomerics to Advance NB1111 for the Treatment of Glaucoma Using Molecular Envelope Technology

Nemus Bioscience announced that the company has signed a development agreement with Nanomerics of the United Kingdom to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinat…

Read the full story

Monday, March 20, 2017 | Clinical Trials, Retina

NightstaRx Commences First Phase 1/2 Gene Therapy Clinical Trial for Patients with X-Linked Retinitis Pigmentosa

NightstaRx, a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, today announces that the company has commenced enrolling and dosing subjects in a p…

Read the full story
Load More